Johnson & Johnson
This article was originally published in The Gray Sheet
Firm's Cordis subsidiary currently has no plans to submit a PMA supplement for elective stenting with its Mini Crown coronary stent system, as was earlier being considered by the company ("The Gray Sheet" April 26, p. 7). The device, available in diameters of 2.25-3.25 mm, is approved for treatment of abrupt or threatened closure in patients with failed interventional therapy in native coronary lesions. Approval of 2.5 mm versions of competing stents from Guidant (Duet) and Boston Scientific (Nir) also is limited to abrupt or threatened closure, although 3.0 mm and larger versions of those devices are approved for broader indications for first-line therapy
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.